Clinical and Experimental Nephrology

, Volume 11, Issue 4, pp 261–268

CKD-MBD: impact on management of kidney disease

  • Hiroaki Ogata
  • Fumihiko Koiwa
  • Eriko Kinugasa
  • Tadao Akizawa
REVIEW ARTICLE

DOI: 10.1007/s10157-007-0492-5

Cite this article as:
Ogata, H., Koiwa, F., Kinugasa, E. et al. Clin Exp Nephrol (2007) 11: 261. doi:10.1007/s10157-007-0492-5

Abstract

Chronic kidney disease (CKD) causes various bone mineral disorders, which have recently been named CKD mineral and bone disorder (CKD-MBD). CKD-MBD is associated with extremely high cardiovascular disease (CVD) morbidity and mortality in the endstage kidney disease (ESKD) population. Thus, optimal management of CKD-MBD would lead to a reduction in cardiovascular morbidity and mortality in uremic patients. In addition, it has been suggested that the treatment of CKD-MBD has some favorable effects on the progression of CKD. Recently, novel therapeutic agents, including active vitamin D analogues, noncalcium-containing phosphate binders, and cinacalcet, have become clinically available. In this article, we review novel therapeutic strategies for CKD-MBD.

Key words

CKD CKD-MBD Cardiovascular disease Vitamin D Mineral metabolism 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Copyright information

© Japanese Society of Nephrology 2007

Authors and Affiliations

  • Hiroaki Ogata
    • 1
  • Fumihiko Koiwa
    • 2
  • Eriko Kinugasa
    • 1
  • Tadao Akizawa
    • 3
  1. 1.Department of Internal MedicineShowa University Northern Yokohama HospitalYokohamaJapan
  2. 2.Division of Nephrology, Department of Internal MedicineShowa University Fujigaoka HospitalYokohamaJapan
  3. 3.Department of NephrologyShowa University School of MedicineTokyoJapan

Personalised recommendations